Roche halts Phase I trial

Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and development partner Maxygen are conducting Phase I trials of R7025 for Hepatitis C and Hepatitis B.

"We don't yet know how this will impact the future timing or advancement of the program. Roche has now started additional work to assess the meaning and significance of these results. We will provide an update once all relevant information is collected and evaluated," said Russell Howard, Maxygen's CEO. Back in March Roche opted out of another co-development deal with Maxygen for acute bleeding indications.

- see this release from Maxygen